THE PATENT AND TRADEMARK OFFICE IS RESPECTFULLY REQUESTED TO PLACE ITS STAMP ON THIS POSTAL CARD AND PLACE IT IN OUTGOING MAIL TO SHOW THE FOLLOWING PAPERS . . . VE BEEN RECEIVED.

Militaria de la compressa de la final de la compressa de la compressa de la compressa de la compressa de la co

LEYDIG, VOIT & MAYER LTD CHICAGO, IL 60601-6780

INVOICE NUMBER DATE 02/17/2000 161192/NIH

Saavedra et al. U.S. Serial No. 08/837,812

AMENDMENT - Certificate of Mailing

Form PTO-1083

\$380.00 check - two-month extension fee

February 17, 2000 Due Date: February 17,

Mailed:

Case 161192

BMG/mjc

LH

CHECK *ያ*ጀ/፻7/2000 ዕዕር

TOTAL

380.00

122022

LEYDIG, VOIT & MAYER LTD.

180 N. STETSON TWO PRUDENTIAL PLAZA SUITE 4900 • CHICAGO, IL 60601-6780 PH (312) 616-5600

AMERICAN NATIONAL BANK TRUST COMPANY OF CHICAGO CHICAGO, IL 60690

2-77/710

Three Hundred Eighty and No/100 Dollars PAY:

NUMBER 000122022

ी ORIGINAL DOCUMENT IS PRINTED ON CHEMICAL REACTIVE PAPER & HAS A MICROPRINTED BORDER अ

DATE 02/17/2000

AMOUNT ******380.00

ASSISTANT COMMISSIONER FOR PATENTS

R

OF

@ THE REVERSE SIDE OF THIS DOCUMENT INCLUDES AN ARTIFICIAL WATERMARK - HOLD AT AN ANGLE TO VIEW. @ #122022# #071000770# 00885975#

Attorney Docket No. 161192 Date: February 17, 2000

In re Application of: Saav dra et al.

Serial No.

08/837,812 April 22, 1997

Filed: For:

Biopolymer-Bound Nitric Oxide-Releasing Compositions, Pharmaceutical Compositions

Incorporating Same and Methods of Treating Biological Disorders Using Same

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:	-							
Transmitted herew	rith is a response t	o an office	action in the subje	ect applicatio	n.			
Small entity status of this application under 37 C.F.R. §§ 1.9 and 1.27 has been established by a verified statement previously submitted.								
☐ A verified state	ement to establish	small entit	y status under 37	C.F.R. §§ 1.9	9 and 1.27 is	s enclosed.		
Applicant(ctension Of Time (s) petitions for a file). (s) believes that in deemed necessal on timely. Please of	o petition :	for an extension on the following for the follow	of time is ne	cessary. Ho	owever, to to on of time to	he extent the render the	nat such
No additional of the control of the contro	claim fee is require	ed.						
Other:								
The claim fee has	been calculated a	s shown be	elow:					
·					SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	EXTRA CLAIMS PRESENT	RATE	ADDIT. CLAIM FEE	RATE	ADDIT CLAIM FEE
TOTAL		Minus		=	x 9=	\$	x 18=	\$
INDEPENDENT		Minus		=	x 78=	\$	x 39=	\$
FIRST PRESENTATION OF MULTIPLE CLAIM					+ 260=	\$	+ 130=	\$
					TOTAL	\$	TOTAL	\$
_	e my Deposit Acco				duplicate c	opy of this s	sheet is atta	ched.

In the Commissioner is hereby authorized to charge payment of the following fees associated with this communication

or credit any overpayment to Deposit Account No. 12-1216. A duplicate copy of this sheet is attached.

Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.

Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

LEYDIG, VOIT & MAYER, LTD.

Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Bruce M. Gagala, Reg. No. 28,844 One of the Attorneys for Applicant(s)

Attorney Docket No. 161192

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Saavedra et al.

Group Art Unit: 1502

Serial No. 08/837,812

Examiner: P. Kulkosky

Filed: April 22, 1997

For: Biopolymer-Bound Nitric Oxide-Releasing Compositions, Pharmaceutical Compositions Incorporating Same And Methods Of Treating Biological Disorders Using Same

AMENDMENT

Assistant Commissioner For Patents Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 17, 1999, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE CLAIMS:

1. (Amended) A polymeric composition capable of releasing nitric oxide, said composition comprising (i) a biopolymeric backbone wherein said backbone is of [an oligonucleotide, a nucleic acid,] a tissue-specific antibody or fragment thereof, a cell-specific antibody or fragment thereof, a tumor-specific antibody or fragment thereof, a protein containing a recognition sequence for a receptor-ligand interaction favorable to [tumor] cell or tissue selective attachment, an anti-chemotactic agent, or a hormone, wherein said backbone includes at least one amino group or at least one carboxyl group or combinations thereof, and (ii) at least one nitric oxide-releasing N₂O₂ functional group selected from the group consisting of X+(O)NO] and [N(O)NO+X, wherein X is an organic moiety covalently bonded to said [N₂O₂], and wherein the [N₂O₂] group is covalently bonded in said polymeric composition at one